Rheumatoid Arthritis
Conditions
Interventions
None listed
Sponsors
Fukuoka Rheumatoid Arthritis Biologics Registry (FRABR)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Both genders at more than 20 years old. 2) Patients providing written informed consent. 3) Patients with administration of abatacept (orencia) as a treatment of rheumatoid arthritis. Note1: Give it when an effect is insufficient, even if an appropriate treatment with at least one anti-rheumatic drug is performed in past treatment. Note2: Do not use anti-TNF antibody together with this drug. In addition, avoid combination because the effectiveness and the safety about combination of this drug and other biologics (BIO) are not established.
Exclusion criteria
Exclusion criteria: 1) Patients with history of hypersensitivity to the content of abatacept. 2) Patients with severe infection. 3) Any other patients who are regarded as unsuitable for this study by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship between pre anti-CCP antibody titer and baseline change of SDAI at 24wks, 52wks and 104wks after abatacept administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Relationship between pre anti-CCP antibody titer and baseline change of DAS28-ESR and DAS28-CRP at 24wks, 52wks and 104wks after abatacept administration. 2) Relationship between pre anti-CCP antibody titer and baseline change of QOL improvement effect by using mHAQ at 24wks, 52wks and 104wks after abatacept administration. 3) Baseline change of ant-CCP antibody titer and RF at 12wks, 24wks, 52wks, 76wks and 104months after abatacept administration. 4) Baseline change of MMP-3 at 12wks, 24wks, 52wks, 76wks and 104wks after abatacept administration. | — |
Countries
Japan
Contacts
Public ContactTomomi Tsuru
PS Clinic Department of Rheumatology
Outcome results
None listed